Wellbeing

Sun Pharma commences Phase 2 clinical trial for psoriasis drug

Sun Pharma on Monday said it has initiated Phase 2 clinical trial for a product being developed to treat patients with moderate to severe plaque psoriasis.

migrator

New Delhi

The Phase 2 study is a randomised, double-blind, placebo-controlled study to assess the efficacy and safety of SCD-044 (novel molecule) in the treatment of moderate to severe plaque psoriasis, Sun Pharmaceutical Industries said in a statement. 

The study will enrol around 240 subjects and topline results are expected in 2022, it added. 

SCD-044 is also being evaluated in other autoimmune disorders and Phase 2 studies for other indications like atopic dermatitis, are also expected to be initiated soon, the Mumbai-based drug major said. 

In May last year, Sun Pharma entered into a worldwide in-licensing agreement with Sun Pharma Advanced Research Company Ltd (SPARC) for the development and commercialisation of SCD-044.

Visit news.dtnext.in to explore our interactive epaper!

Download the DT Next app for more exciting features!

Click here for iOS

Click here for Android

Also Read

Tamil Nadu: 6.05 lakh travel on special buses as Pongal rush builds up

Rahul raps Centre for ‘blocking’ Vijay flick

Joy Crizildaa agrees to remove social media posts against Madhampatty Rangaraj’s firm

Death toll from nationwide protests in Iran spikes to at least 2,000, activists say

Vehicle damaged as heavy rains lash Coonoor